Retrospective and Prospective Disease Progression and Quality of Life in XLH

X-linked Hypophosphatemia (XLH) Clinical Trial

Official title:

Retrospective and Prospective Disease Progression and Quality of Life in X-linked Hypophosphatemia (XLH)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04049877
• Other study ID #: Med_Asst19
• Status: Completed
• Start date: July 7, 2019
• Est. completion date: July 28, 2021

Study information

• Verified date: October 2023
• Source: Medialis Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

There is limited empirical data documenting disease progression and impact on quality of life for patients with X-linked hypophosphatemia (XLH). This study seeks to investigate the impact of XLH in adults living in the UK retrospectively and prospectively over a 12 month period, using qualitative interviews, SEIQoL-DW, EQ-5D-5L, SF36 quality of life tools.

XLH is a rare, genetic, chronically debilitating and deforming condition (www.nice.org.uk/guidance/HST8). XLH is characterised by renal phosphate wasting, hypophosphatemia and defective bone mineralisation. The incidence of XLH is reported to be between 1:20,000 and 1:25,000 live births. In the UK, it is estimated that there are around 250 paediatric XLH patients and around 2,500 adult XLH patients (Delmestri,et al [Unpublished report]2018). The clinical phenotype of XLH is varied amongst patients, even among affected members of the same family. This can range from no signs or symptoms, slow growth in children, short stature, bone abnormalities that can affect movement and result in pain, bowed legs and knocked knees (where lower legs are positioned at an outward angle), tooth abscesses and excessive dental caries and hearing loss (adult patients only).

This study will recruit 36 adults living with XLH, who are aged 28 years or over and living in the UK. The study will be advertised by the Sponsor and funder Medialis Ltd and via the patient organisation Metabolic Support UK. All study activities will take place via tele-visits and online questionnaires. The study will last approximately 2 years, allowing for one-year recruitment and a further 12 months to conduct all study visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: July 28, 2021
• Est. primary completion date: February 28, 2021
• Gender: All
• Age group: 28 Years and older

Eligibility

Inclusion Criteria:

• • Participant has a diagnosis of XLH

• Participant is aged 28 years and above.

• Participant is capable of providing informed consent

• Participant is able to read and converse in English

• Participant is able to comply with the study schedule (5 tele-visits over a 12-month period)

Exclusion Criteria:

• • Participant does not have a diagnosis of XLH

• Participant is aged under 28 years

• Participant is not capable of giving informed consent

• Participant is unable to read and converse in English

• Participant is unable to comply the with study schedule (5 tele-visits over a 12-month period)

Related Conditions & MeSH terms

• Disease Progression
• Familial Hypophosphatemic Rickets
• Hypophosphatemia
• X-linked Hypophosphatemia (XLH)

Intervention

Other:
• None - Observational study
None - Observational study

Locations

Country	Name	City	State
United Kingdom	Medialis	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
Medialis Ltd.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Schedule for the Evaluation of Individual Quality of Life Direct Weight (SEIQoL-DW)	Change in quality of life	12 months
Primary	Disease progression in adults living with XLH	Qualitative investigation of disease progression	12 months
Secondary	EQ- 5D-5L	Quality of life measure	12 months
Secondary	SF36	Quality of life measure	12 months

External Links

•   This is a link to the publication resulting from this study.